Calamos Advisors LLC lifted its stake in shares of Baxter International Inc (NYSE:BAX) by 0.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,355,732 shares of the medical instruments supplier’s stock after purchasing an additional 9,391 shares during the period. Calamos Advisors LLC owned 0.25% of Baxter International worth $104,513,000 at the end of the most recent quarter.
Several other hedge funds also recently modified their holdings of the company. Bridgeworth LLC bought a new position in Baxter International in the 2nd quarter worth approximately $102,000. Migdal Insurance & Financial Holdings Ltd. boosted its holdings in Baxter International by 3,088.9% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,435 shares of the medical instruments supplier’s stock worth $106,000 after buying an additional 1,390 shares during the period. Baker Ellis Asset Management LLC bought a new position in Baxter International in the 2nd quarter worth approximately $111,000. Centaurus Financial Inc. bought a new position in Baxter International in the 2nd quarter worth approximately $117,000. Finally, Whittier Trust Co. of Nevada Inc. boosted its holdings in Baxter International by 84.4% in the 2nd quarter. Whittier Trust Co. of Nevada Inc. now owns 1,748 shares of the medical instruments supplier’s stock worth $126,000 after buying an additional 800 shares during the period. Institutional investors own 83.16% of the company’s stock.
BAX has been the subject of several analyst reports. Zacks Investment Research raised shares of Baxter International from a “hold” rating to a “buy” rating and set a $87.00 price objective for the company in a report on Tuesday, September 25th. Royal Bank of Canada reissued a “hold” rating and issued a $76.00 price target on shares of Baxter International in a report on Friday, July 27th. Argus reissued a “hold” rating on shares of Baxter International in a report on Tuesday, September 4th. Citigroup raised their price target on shares of Baxter International from $74.00 to $76.00 and gave the company a “neutral” rating in a report on Tuesday, July 31st. Finally, Piper Jaffray Companies raised their price target on shares of Baxter International from $77.00 to $83.00 and gave the company an “overweight” rating in a report on Friday, July 27th. Two analysts have rated the stock with a sell rating, four have given a hold rating and nine have given a buy rating to the company’s stock. Baxter International currently has a consensus rating of “Hold” and an average price target of $77.77.
Shares of Baxter International stock traded down $0.46 on Monday, hitting $69.00. 330,102 shares of the company traded hands, compared to its average volume of 2,866,295. The company has a debt-to-equity ratio of 0.39, a quick ratio of 2.00 and a current ratio of 2.62. The stock has a market cap of $37.11 billion, a P/E ratio of 27.82, a price-to-earnings-growth ratio of 1.88 and a beta of 0.77. Baxter International Inc has a 12-month low of $62.52 and a 12-month high of $78.38.
Baxter International (NYSE:BAX) last posted its quarterly earnings data on Thursday, July 26th. The medical instruments supplier reported $0.77 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.71 by $0.06. The firm had revenue of $2.84 billion for the quarter, compared to analysts’ expectations of $2.83 billion. Baxter International had a net margin of 8.29% and a return on equity of 16.63%. The business’s quarterly revenue was up 9.1% on a year-over-year basis. During the same quarter last year, the company posted $0.63 EPS. On average, analysts predict that Baxter International Inc will post 2.98 earnings per share for the current year.
Baxter International Company Profile
Baxter International Inc provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.